TG Therapeutics, Inc..
TGTX.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company's primary focus is on developing and commercializing therapies for patients with diseases such as chron...Show More
Better Health for All
-40
TG Therapeutics' primary marketed product, BRIUMVI for multiple sclerosis, demonstrates substantial health benefits, with 92% of patients free from disability progression and an annualized relapse rate of 0.02 in five-year study data.
1
The company no longer generates revenue from products with significant negative health impacts, as Ukoniq was voluntarily withdrawn in June 2022 due to an increased risk of death.
2
However, this withdrawal represents a notable safety incident within the last three years. BRIUMVI is priced at $59,000 per year, which the Institute for Clinical and Economic Review (ICER) considers not cost-effective, recommending a price requiring at least a 59% discount.
3
While financial assistance programs exist for commercially insured and uninsured patients, specific data on the percentage of those in need reached is not provided.
4
The company provides detailed safety information for BRIUMVI, but the withdrawal of Ukoniq due to safety concerns indicates past issues with risk transparency.
5
TG Therapeutics allocated $46.4 million to R&D in Q1 2025, but the percentage of this budget specifically aimed at improving health outcomes and accessibility is not disclosed.
6
The company supports healthcare workforce development through a fellowship program, offering up to $100,000 per academic year for MS specialist training.
7
The company does not currently have an expanded access program for investigational therapies.
8
No information is available regarding the company's approach to patents in relation to global health needs. The company's clinical trials for BRIUMVI (ULTIMATE I & II, ENHANCE) are mentioned, but no specific details on ethical conduct, diversity, or transparency are provided beyond the positive outcomes.
9
Fair Money & Economic Opportunity
0
No evidence available to assess TG Therapeutics, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
10
As of fiscal year ending 2024, the CEO-to-median employee pay ratio was 58:1.
1
None of the company's 264 full-time employees are represented by a collective bargaining agreement, and the company has never experienced a work stoppage.
2
Fair Trade & Ethical Sourcing
0
No evidence available to assess TG Therapeutics, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
0
No evidence available to assess TG Therapeutics, Inc. on Honest & Fair Business.
Kind to Animals
-60
TG Therapeutics conducts animal testing for its clinical analysis and medical products, as evidenced by its use of animal models in research.
1
There is no explicit animal testing policy mentioned in the provided documents.
2
The company uses between 50,000 and 100,000 animals annually, with no transparent reduction targets or publicly available data on the exact number of animals used.
No War, No Weapons
0
No evidence available to assess TG Therapeutics, Inc. on No War, No Weapons.
Planet-Friendly Business
0
The provided articles do not contain any specific, concrete data points or verifiable facts related to TG Therapeutics' planet-friendly business practices. Therefore, no KPIs can be scored against the rubric.
Respect for Cultures & Communities
0
No evidence available to assess TG Therapeutics, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
No evidence available to assess TG Therapeutics, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No evidence available to assess TG Therapeutics, Inc. on Zero Waste & Sustainable Products.